Total Payments
$207,211
2024 Payments
$14,172
Companies
23
Transactions
194
Medicare Patients
1,374
Medicare Billing
$197,152
Payment Breakdown by Category
Other$92,911 (44.8%)
Consulting$68,914 (33.3%)
Travel$29,246 (14.1%)
Food & Beverage$8,945 (4.3%)
Research$7,186 (3.5%)
Education$9.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $68,914 | 34 | 33.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,813 | 23 | 30.8% |
| Travel and Lodging | $29,246 | 27 | 14.1% |
| Honoraria | $20,070 | 8 | 9.7% |
| Food and Beverage | $8,945 | 96 | 4.3% |
| Unspecified | $7,186 | 1 | 3.5% |
| Grant | $5,000 | 1 | 2.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,710 | 2 | 1.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $318.36 | 1 | 0.2% |
| Education | $9.42 | 1 | 0.0% |
Payments by Type
General
$200,026
193 transactions
Research
$7,186
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $71,195 | 64 | $0 (2024) |
| Advanced Accelerator Applications | $42,586 | 22 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $17,128 | 23 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $13,685 | 21 | $0 (2020) |
| TerSera Therapeutics LLC | $9,120 | 7 | $0 (2024) |
| Novartis Pharma AG | $8,917 | 7 | $0 (2018) |
| Sun Pharmaceutical Industries Inc. | $8,800 | 4 | $0 (2020) |
| Terumo Medical Corporation | $7,875 | 7 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $6,675 | 2 | $0 (2023) |
| Exelixis Inc. | $5,727 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,172 | 23 | Exelixis Inc. ($5,727) |
| 2023 | $5,185 | 8 | Boehringer Ingelheim International GmbH ($4,400) |
| 2022 | $23,974 | 22 | Ipsen Biopharmaceuticals, Inc ($14,568) |
| 2021 | $28,479 | 20 | Ipsen Biopharmaceuticals, Inc ($14,235) |
| 2020 | $23,793 | 10 | Advanced Accelerator Applications ($12,773) |
| 2019 | $25,193 | 20 | Ipsen Biopharmaceuticals, Inc ($21,915) |
| 2018 | $45,507 | 41 | Advanced Accelerator Applications ($15,044) |
| 2017 | $40,908 | 50 | Advanced Accelerator Applications ($14,605) |
All Payment Transactions
194 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,960.00 | General |
| 12/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $580.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $132.43 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/22/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $65.96 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $339.29 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/28/2024 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $125.14 | General |
| 09/25/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $55.94 | General |
| Category: Oncology | ||||||
| 07/18/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $133.50 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Ipsen Biopharmaceuticals, Inc | Somatuline Depot (Drug) | Food and Beverage | In-kind items and services | $146.18 | General |
| Category: Oncology/Endocrinology | ||||||
| 05/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $1,020.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/15/2024 | Curium US LLC | — | Honoraria | Cash or cash equivalent | $3,250.00 | General |
| 05/09/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $149.89 | General |
| Category: Oncology | ||||||
| 05/05/2024 | Curium US LLC | — | Travel and Lodging | Cash or cash equivalent | $245.79 | General |
| 05/05/2024 | Curium US LLC | — | Food and Beverage | Cash or cash equivalent | $145.97 | General |
| 05/04/2024 | Curium US LLC | — | Travel and Lodging | Cash or cash equivalent | $335.01 | General |
| 05/04/2024 | Curium US LLC | — | Travel and Lodging | Cash or cash equivalent | $278.20 | General |
| 05/04/2024 | Curium US LLC | — | Travel and Lodging | Cash or cash equivalent | $274.85 | General |
| 05/04/2024 | Curium US LLC | — | Food and Beverage | Cash or cash equivalent | $143.71 | General |
| 04/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/05/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $117.00 | General |
| Category: Oncology | ||||||
| 04/03/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $143.44 | General |
| Category: Oncology | ||||||
| 11/09/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $114.51 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Ipsen Biopharmaceuticals, Inc | Somatuline Depot (Drug), Onivyde | Food and Beverage | In-kind items and services | $130.40 | General |
| Category: Oncology/Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 322 | 432 | $93,039 | $42,843 |
| 2022 | 4 | 346 | 531 | $113,420 | $55,203 |
| 2021 | 5 | 365 | 561 | $109,691 | $58,083 |
| 2020 | 5 | 341 | 478 | $97,594 | $41,024 |
Total Patients
1,374
Total Services
2,002
Medicare Billing
$197,152
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 124 | 161 | $38,353 | $18,587 | 48.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 93 | 140 | $24,920 | $11,017 | 44.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 41 | $9,809 | $4,631 | 47.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $6,144 | $2,642 | 43.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $5,448 | $2,348 | 43.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 28 | $4,935 | $2,125 | 43.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 28 | $3,430 | $1,494 | 43.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 156 | 238 | $53,968 | $27,159 | 50.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 52 | 72 | $16,354 | $8,269 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 99 | $16,793 | $7,778 | 46.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $8,801 | $4,024 | 45.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $7,527 | $3,416 | 45.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 29 | $4,900 | $2,288 | 46.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 43 | $5,077 | $2,267 | 44.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 139 | 210 | $45,330 | $24,950 | 55.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 70 | 125 | $19,200 | $10,090 | 52.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 76 | $16,490 | $9,062 | 55.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 31 | 31 | $10,075 | $4,612 | 45.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 31 | 66 | $6,608 | $3,623 | 54.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $5,200 | $2,416 | 46.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 26 | $4,038 | $2,105 | 52.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 11 | 11 | $2,750 | $1,224 | 44.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 143 | 200 | $43,000 | $17,983 | 41.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 43 | 64 | $13,760 | $5,866 | 42.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 39 | 39 | $12,675 | $5,367 | 42.3% |
About Dr. Jonathan Strosberg, MD
Dr. Jonathan Strosberg, MD is a Medical Oncology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013960988.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Strosberg, MD has received a total of $207,211 in payments from pharmaceutical and medical device companies, with $14,172 received in 2024. These payments were reported across 194 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($68,914).
As a Medicare-enrolled provider, Strosberg has provided services to 1,374 Medicare beneficiaries, totaling 2,002 services with total Medicare billing of $197,152. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Tampa, FL
- Active Since 05/19/2006
- Last Updated 01/22/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1013960988
Products in Payments
- SOMATULINE DEPOT (Drug) $52,830
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $27,578
- Xermelo (Drug) $16,604
- LUTATHERA (Drug) $13,317
- Somatuline Depot 120mg-.5ml (Drug) $10,897
- AFINITOR (Drug) $10,565
- SANDOSTATIN (Drug) $9,008
- BYNFEZIA PEN (Drug) $8,800
- Somatuline Depot (Drug) $5,991
- SANDOSTATIN LAR (Drug) $5,664
- CABOMETYX (Drug) $5,602
- NETSPOT (kit for the preparation of gallium Ga 68 dotatate for injection) (Drug) $2,071
- MYCAPSSA (Drug) $1,881
- Quzyttir (Drug) $1,746
- Somatuline (Drug) $1,575
- Onivyde (Drug) $1,477
- Avastin (Biological) $681.17
- Cabometyx (Drug) $600.00
- Nerlynx (Drug) $318.36
- Lutathera (Drug) $164.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Tampa
Dr. Richard Kim, M. D, M. D
Medical Oncology — Payments: $844,688
Medical Oncology $844,688
Kenneth Shain, M.d, M.D
Medical Oncology — Payments: $394,889
Medical Oncology $394,889
Dr. Julio Chavez, Md, MD
Medical Oncology — Payments: $360,060
Medical Oncology $360,060
Ivan Borrello, M.d, M.D
Medical Oncology — Payments: $338,320
Medical Oncology $338,320
Dr. Jingsong Zhang, M.d, M.D
Medical Oncology — Payments: $254,025
Medical Oncology $254,025
Dr. Sameh Gaballa, Md, MD
Medical Oncology — Payments: $201,569
Medical Oncology $201,569